WallStSmart
BFRI

Biofrontera Inc

NASDAQ: BFRI · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC

$1.08
-1.82% today

Updated 2026-04-30

Market cap
$12.58M
P/E ratio
P/S ratio
0.30x
EPS (TTM)
$-1.04
Dividend yield
52W range
$1 – $1
Volume
0.1M

Biofrontera Inc (BFRI) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
4 of 8
Last 8 quarters
Avg EPS surprise
+29.0%
Last 4 quarters
Revenue YoY growth
+36.2%
Most recent quarter
EPS YoY growth
+314.7%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
-7.1%
Last 2 reports
Positive reaction rate
50%
1 of 2 quarters
Largest single-day move
-14.4%
2025-11-12
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-03-19$0.50+398.1%$0.87$0.87+0.2%
2025-11-12$-0.62-8.8%$1.04$0.89-14.4%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$0.10$0.50+398.1%$17.10M+36.2%
2025-09-30$-0.57$-0.62-8.8%$6.99M-22.5%
2025-06-30$-0.57$-0.57+0.0%$9.03M+15.2%
2025-03-31$-0.29$-0.51-75.3%$8.59M+8.7%
2024-12-31$-0.07$-0.23-231.4%$12.56M+18.5%
2024-09-30$-0.83$-0.81+2.0%$9.01M+1.3%
2024-06-30$-0.77$-0.05+93.5%$7.84M+34.0%
2024-03-31$-1.17$-2.88-146.2%$7.90M-9.5%
2023-12-31$-1.19$1.65+238.7%$10.60M
2023-09-30$-3.78$-4.64-22.8%$8.90M
2023-06-30$-4.61$-7.23-56.8%$5.85M
2023-03-31$-0.19$-0.28-47.4%$8.73M

Frequently asked questions

Has Biofrontera Inc beaten earnings estimates?
Biofrontera Inc has beaten Wall Street EPS estimates in 4 of its last 8 quarterly reports, with an average EPS surprise of +29.0% over the last 4 quarters.
How does BFRI stock react to earnings?
BFRI stock has moved an average of -7.1% in the trading day following earnings over its last 2 reports, with positive reactions in 50% of those quarters.
What is Biofrontera Inc's revenue growth rate?
Biofrontera Inc reported year-over-year revenue growth of +36.2% in its most recent quarter, with EPS growing +314.7% year-over-year.